
Magle Chemoswed Q4 - Delivering on its growth trajectory

Redeye provides a research update following the Q4 report recently published by Magle. The company continues to report record-high sales figures at SEK87.2, a 52% y/y growth, and a promising EBITDA margin at 24% following the integrations of pK Chemicals and Amniotics. As the company has now strengthened its financials through recent share issues, we believe that the new Magle Group is poised to continue its growth and generate further shareholder value ahead.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Magle Chemoswed Q4 - Delivering on its growth trajectory](#)